Enhancing Patient Engagement Efforts across FDA

As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2017 about Enhancing Patient Engagement Efforts across FDA can be found below.

Enhancing Patient Engagement Efforts across FDA

Scroll to Top